Comparing Radiation Therapies for Prostate Cancer
Name of the Trial
Why This Trial Is Important
Some studies suggest that a conventional 8- to 10-week course of radiotherapy may not be the most effective or economical way of treating these patients. Consequently, researchers are studying whether increasing the dose of radiation during each day of treatment and delivering the total radiation dose over a shorter period of time (called hypofractionated radiotherapy) may be an equally effective approach to treating prostate cancer.
In this trial, men with favorable-risk, localized prostate cancer will be randomly assigned to receive conventionally fractionated radiation therapy over the course of about 8 weeks (41 daily treatments) or hypofractionated radiotherapy over a 5-and-a-half-week period (28 daily treatments).
"Previous studies of hypofractionated radiotherapy were not designed to tell us if the technique works as well as conventional regimens in terms of helping patients live longer without recurrence of their cancer," said Dr. Lee. "This trial is designed to answer that question."
"If we determine that we can deliver radiation over a shorter period of time with similar efficacy, we may realize benefits in terms of cost and convenience for patients as well."
Who Can Join This Trial
Study Site and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.